F5 Q1 beats with 7% revenue growth and higher FY26 guidance, driven by AI wins and buybacks—but premium valuation adds risk.

(Graph) today announced a strategic partnership to create one of the largest and most comprehensive immune cell perturbation atlases. The collaboration will leverage Graph's lab-in-the-loop platform ...

Parse Biosciences & Graph Therapeutics partner to build large functional immune perturbation atlas: Seattle Thursday, January 22, 2026, 11:00 Hrs [IST] Parse Biosciences, a global ...

American Beacon GLG Natural Resources ETF has high HBM and KGC exposure and high turnover at a premium to NAV. Check out why ...

Women’s health is moving beyond stigma as data, investment and patient-led tools begin reshaping care, research and who gets ...

One major benefit of HISA was a national system that aggregates racehorse veterinary records into a single, searchable ...

With extreme weather-related storms and growing power demand, it required a shift to an end-to-end modernization strategy for ...

After years of following crypto from early Bay Area events to endless online discussions, one pattern stands out: the market ...

Tourmaline, a dividend stock committed to paying out 100% of its excess free cash flow in dividends, is a passive-income ...

The strategic pivot must be toward the "infrastructure layer"; comprising sovereign cloud architectures, orbital computing ...

A profound transformation is taking place in therapeutic discovery, development, and delivery.2026 will be a pivotal year for biopharma. From digital transformation to an AI revolution to more ...